Clearmind Completes Phase I/IIa Trial Milestone for Alcohol Use Disorder Drug

Event summary

  • Clearmind Medicine completed treatment and follow-up for 18 participants in its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder (AUD).
  • Four additional participants were treated at the Tel Aviv clinical site, expanding enrollment.
  • The trial is evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in moderate to severe AUD patients.
  • The study is being conducted at leading institutions including Yale University, Johns Hopkins University, and two Israeli medical centers.

The big picture

This milestone represents significant progress for Clearmind's lead candidate in addressing Alcohol Use Disorder, a condition with limited effective treatments. The company is positioning itself at the forefront of non-hallucinogenic psychedelic-derived therapies, competing with other biotechs developing similar approaches but without the same proprietary MEAI-based formulation. Success here could validate Clearmind's platform approach to neuroplastogen therapeutics beyond just AUD.

What we're watching

Trial Momentum
Whether Clearmind can sustain this rapid enrollment pace across all international sites.
Regulatory Pathway
How the FDA will view these interim results as the trial progresses toward later phases.
Competitive Positioning
The pace at which Clearmind can differentiate CMND-100 in the emerging neuroplastogen therapeutics market.

Related topics

Pharmaceuticals